Patent & IP news for March 17, 2012

Some interesting facts about the Indo-E.U. dispute over the seizure of ‘in-transit’ pharmaceuticals from spicyipindia.blogspot.com

It has been almost two years since India filed a complaint against the E.U., with the WTO, regarding the seizure of pharmaceutical consignments that were transiting through the ports at E.U. India was ...

Share via E–mail | Twitter | Facebook

Anti-piracy movement in India gains heat: Cause for concern or justified response? from spicyipindia.blogspot.com

Unsatisfied with the court order it recently obtained from the Calcutta High Court, granting an ex-parte injunction against the website www.songs.pk, the Indian Music Industry (‘IMI’) has gone all out against more than ...

Share via E–mail | Twitter | Facebook

Singapore and the US Divergent Patent Policies from hallingblog.com

While the US continues to weaken its patent laws, Singapore is taking a different path.  Singapore has just announced that it is developing a plan to be an Intellectual Property Hub, according to Channelnewsasia.com ...

Share via E–mail | Twitter | Facebook

Webinar on FDA's Biosimilar Guidance from www.patentdocs.org

The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "The FDA's Guidance on Biosimilars: Understanding the Impact on Patent Prosecution and Litigation" on March 22, 2012 beginning at 2:00 pm ...

Share via E–mail | Twitter | Facebook

BIO IPCC Spring Conference from www.patentdocs.org

The Biotechnology Industry Organization (BIO) will be holding its Intellectual Property Counsels Committee (IPCC) Spring Conference & Meeting on April 16-18, 2012 in Austin, TX. The semi-annual IPCC conference will once again be open to the ...

Share via E–mail | Twitter | Facebook

Patent Searching 101: A Patent Search Tutorial from www.ipwatchdog.com

Once you receive manageable results you need to read the patents and see which ones are relevant. Try various search terms to make sure you are covering all possible descriptions of the invention. Along the ...

Share via E–mail | Twitter | Facebook

Rejections based upon "mere design choice" from ipbiz.blogspot.com

The 717MadisonPlace blog notes the words of Judge Linn on "mere design choice" -->

I can remember way back when when I was an examiner, some of the toughest problems we faced were when we went ...

Share via E–mail | Twitter | Facebook

The impact of free licensing on innovation? from ipbiz.blogspot.com

According to Gilad Sorek in an article to be published in Economics Letters Firms that make a previously patented innovation accessible to competitors increase overall likelihood of improving upon that breakthrough while also raising profits ...

Share via E–mail | Twitter | Facebook

The prison on Central Park from ipbiz.blogspot.com

An 2002 article in The Morning News titled Prison on the Park described the Lincoln Correctional Facility, located on the north side of New York's Central Park, and ended with the text:

The five ...

Share via E–mail | Twitter | Facebook

German courts appear inclined to halt one Microsoft-Motorola and another Apple-Samsung lawsuit from fosspatents.blogspot.com

A busy smartphone-related court schedule in Munich (yesterday) and Mannheim (today) has resulted in a backlog of trials for me to report on. I always prioritize decisions over trials and pleadings.

I've previously blogged ...

Share via E–mail | Twitter | Facebook

SME Trademark Applicants Should Beware of Scams from dcipattorney.com

Many of my small- and medium-sized enterprise (SME) clients who have filed U.S. trademark applications have been contacting me lately about “invoices” they have received in the mail.  All of these official-looking “invoices,” however ...

Share via E–mail | Twitter | Facebook

India Compulory License Update: Blowback Edition from www.patentbaristas.com

Well, I’ve certainly heard from a number of people regarding my earlier post on  the compulsory license granted by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of Bayer ...

Share via E–mail | Twitter | Facebook